ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0525

Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR ≤20 in the Avacopan ADVOCATE Trial

David Jayne1, Peter Merkel2, Frank Cortazar3, John Niles4 and Pirow Bekker5, 1University of Cambridge, Cambridge, United Kingdom, 2U of Pennsylvania, Philadelphia, PA, 3St. Peter's Hospital, Albany, NY, 4Harvard, Boston, MA, 5ChemoCentryx, San Juan Capistrano, CA

Meeting: ACR Convergence 2022

Keywords: ANCA associated vasculitis, clinical trial

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Abstracts: Vasculitis – ANCA-Associated

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: In the 330-patient ADVOCATE trial of avacopan for the treatment of ANCA-associated vasculitis, in which 81% of patients with ANCA-associated vasculitis had renal involvement, estimated glomerular filtration rate (eGFR) increased on average 7.3 mL/min/1.73 m2 in the avacopan group and 4.1 in the prednisone group (P=0.029) at Week 52 (Jayne et al. 2021). The aim of this post hoc analysis was to evaluate changes in eGFR in patients in ADVOCATE who upon enrolment into the trial approached the threshold for dialysis, i.e., eGFR ≤20 mL/min/1.73 m2.

Methods: eGFR (based on serum creatinine and the Modification of Diet in Renal Disease equation) was measured at baseline and over the course of the trial. Data from patients in ADVOCATE with an eGFR ≤20 mL/min/1.73 m2 at baseline were included in this analysis.

Results: In ADVOCATE, 27 of 166 patients (16%) in the avacopan group and 23 of 164 patients (14%) in the prednisone group had a baseline eGFR ≤20 mL/min/1.73 m2. Baseline characteristics were similar across treatment groups (Table 1). The mean age in this low eGFR group of 50 patients was similar to the overall 330-patient population (66 vs. 61 years), but included a higher proportion of patients with newly diagnosed disease (88 vs. 69%), MPO+ (84 vs. 57%), and MPA (72 vs. 45%), and higher use of cyclophosphamide (50 vs. 35%).

Individual eGFR data from all patients are shown in Figure 1. eGFR increased on average 16.1 and 7.7 mL/min/1.73 m2 at Week 52 in the avacopan and prednisone groups, respectively (P=0.003). The last eGFR value measured during the 52-week treatment period was >20 mL/min/1.73 m2 in 85% of patients in the avacopan group compared to 57% of patients in the prednisone group (P=0.024). 41% of patients in the avacopan group had an increase in eGFR of ≥2-fold vs. 13% in the prednisone group (P=0.030). A higher number of patients in the avacopan group had increases in eGFR above 30 and 45 mL/min/1.73 m2, respectively. eGFR in one patient in the avacopan group increased to 65 at Week 52 (baseline 17). Urinary albumin:creatinine ratio levels improved more rapidly in the avacopan vs. prednisone group. Serious adverse events occurred in 13/27 patients (48%) in the avacopan group (1 death due to bronchopneumonia) and 16/23 patients (70%) in the prednisone group (1 death due pleural empyema).

Conclusion: Among patients with baseline eGFR ≤20 mL/min/1.73 m2 in the ADVOCATE trial, eGFR improved more in the avacopan vs. control group.

Supporting image 1

Figure 1: Change from Baseline in eGFR by Treatment Group over the Course of the 52-Week Treatment Period in the ADVOCATE trial of Avacopan for ANCA-associated Vasculitis in Patients with Baseline eGFR ≤20 mL/min/1.73 m2

Supporting image 2

Table 1: Summary of Data on eGFR in the ADVOCATE trial of Avacopan for ANCA-associated Vasculitis in Patients with Baseline eGFR ≤20 mL/min/1.73 m2


Disclosures: D. Jayne, Aurinia, AstraZeneca, GlaxoSmithKline (GSK), Roche/Genentech, Vifor, Bristol-Myers Squibb(BMS), Chemocentryx, Novartis, Takeda, Boehringer-Ingelheim, Otsuka, UCB, Amgen, Kessai; P. Merkel, ChemoCentryx; F. Cortazar, ChemoCentryx; J. Niles, ChemoCentryx; P. Bekker, Chemocentryx.

To cite this abstract in AMA style:

Jayne D, Merkel P, Cortazar F, Niles J, Bekker P. Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR ≤20 in the Avacopan ADVOCATE Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/recovery-of-renal-function-among-anca-associated-vasculitis-patients-with-baseline-egfr-%e2%89%a420-in-the-avacopan-advocate-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/recovery-of-renal-function-among-anca-associated-vasculitis-patients-with-baseline-egfr-%e2%89%a420-in-the-avacopan-advocate-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology